Jan. 12 at 11:13 AM
Baird reiterated
$BNTC Outperform-
$30 and said, Incrementally positive on data update.
Benitec shared updated data from Cohort 1 of the Phase 1b/2a trial of BB-301, with Patient 1 from Cohort 1 having reached 24 months of follow-up and four patients having crossed the 12-month follow-up threshold. Patient 1 maintained PhAMPC improvements while improvements on swallowing residue and SSQ deepened, and Patients 1-4 continue to show robust response on at least three measures of Benitec's responder analysis at 12 months.
Although today's data are mostly incremental, we remain encouraged by the efficacy and safety demonstrated to date.
